Biostar Pharma (BSPM) Tops Q4 Views
Tweet
Share
E-mailGet Alerts BSPM Hot Sheet
Join SI Premium – FREE
Biostar Pharmaceuticals (Nasdaq: BSPM) reported Q4 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.58 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
